Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis
Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W, Harrington A, Wilson C, Tsouros S, Soobiah C, Yu CH, Hutton B, Hoch JS, Hemmelgarn BR, Moher D, Majumdar SR, Straus SE. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ. 2014;349:g5459. doi:10.1136/bmj.g5459.
[sidebar] Commissioned and Funded by: Canadian Institutes of Health Research (CIHR) through the Drug Safety and Effectiveness Network (DSEN)
[/no-bottom-margin]
Share Buttons [span][/span]
[ssba-buttons] [/sidebar] [sidebar-content]- Our results can be used by patients and physicians to tailor administration of these agents
- Conducted for the British Columbia Ministry of Health to inform the decision to continue listing the insulin in the same manner
- Featured in >220 mass media articles
- Used to update the World Health Organization (WHO) Model Lists of Essential Medicines
- Patients receiving detemir once or twice daily experienced significantly fewer episodes of severe hypoglycemia compared to NPH once or twice daily. NPH once daily and detemir once daily caused significantly more weight gain, however, detemir once or twice daily caused significantly less weight gain than NPH once or twice daily
Altmetrics:
Related Projects:
[/sidebar-content]Category : KS Projects
Date : 29 Oct 2019